Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
Introduction: Data from randomized controlled trials show that liraglutide 3.0 mg, in combination with diet and exercise, is associated with greater weight loss than diet and exercise alone in patients with obesity. In practice, the utilization of weight loss drugs is influenced by various factors, including the cost of treatment. We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients’ persistence on treatment, in a real-world setting. Methods: Data were extracted from de-identified electronic medical records from an obesity management clinic in Switzerland. Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71). Results: Median persistence on liraglutide was 6.8 months. Median maximum dose received was 1.5 mg, and 13.7% of patients reached the maintenance dose of 3.0 mg. Mean 7-month weight change from baseline in the full cohort was −4.1 kg (95% confidence interval: −5.0, −3.2; p < 0.001; −4.2%). Weight change was −4.4 kg (−4.7%) in the ≥4-month persistence subgroup at 4 months, −5.1 kg (−5.3%) in the ≥7-month persistence subgroup at 7 months, and −7.5 kg (−7.1%) in the ≥12-month persistence subgroup at 12 months (all p < 0.001). In the full cohort, 40% and 14% of patients lost ≥5% and >10% of body weight at 7 months, respectively. Weight loss did not differ significantly according to history of bariatric surgery (p = 0.94). Diastolic blood pressure decreased (from 87.0 to 83.9 mm Hg at 7 months; p = 0.018), with no significant changes in systolic blood pressure. Approximately two-thirds of patients did not have health insurance that could cover the cost of liraglutide. Conclusion: In a real-world setting with low insurance coverage and with most patients not reaching the recommended maintenance dose of 3.0 mg, the use of liraglutide, in combination with diet and exercise, was associated with clinically meaningful weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Blundell, J. E., Baker, J. L., Boyland, E., Blaak, E., Charzewska, J., de Henauw, S., Frühbeck, G., Gonzalez-Gross, M., Hebebrand, J., Holm, L., et al. (2017) · Obesity Facts · doi:10.1159/000455952 · Cited by 1,945
Influence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials
Neter, J. E., Stam, B. E., Kok, F. J., Grobbee, D. E., & Geleijnse, J. M. (2003) · Hypertension · doi:10.1161/01.hyp.0000094221.86888.ae · Cited by 1,391
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Cefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243
Zomer, E., Gurusamy, K., Leach, R., Trimmer, C., Lobstein, T., Morris, S., James, W. P. T., & Finer, N. (2016) · Obesity Reviews · doi:10.1111/obr.12433 · Cited by 236
Wharton, S., Kuk, J. L., Luszczynski, M., Kamran, E., & Christensen, R. A. G. (2019) · Clinical Obesity · doi:10.1111/cob.12323 · Cited by 144
Cited by
Ghusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14940 · Cited by 40
“Recent real-world data studies have replicated the findings of previous GLP-1RA trials, with significant weight loss achieved, and the weight loss is similar across different doses.(17,18) This reinforces the importance of GLP-1RAs as an effective treatment for weight loss.”
ResultIncretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024) · Diabetes Care · doi:10.2337/dc24-1082 · Cited by 46
Esparham, A., Mehri, A., Dalili, A., Richards, J., & Khorgami, Z. (2024) · Obesity Reviews · doi:10.1111/obr.13811 · Cited by 45
“50 Both liraglutide and semaglutide elicited consistent and dose-dependent weight loss effects.”
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
Santini, S., Vionnet, N., Pasquier, J., Gonzalez‐Rodriguez, E., Fraga, M., Pitteloud, N., & Favre, L. (2023) · Obesity · doi:10.1002/oby.23596 · Cited by 39
“The Swiss insurance reimbursement schema could be another factor contributing to the increased success of the current study, especially compared with the other real-world studies in which patients self-paid for the treatment [18, 19, 21].”
BackgroundResultLin, Q., Xue, Y., Zou, H., Ruan, Z., Ung, C. O. L., & Hu, H. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2130760 · Cited by 38
Samuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70004 · Cited by 35
“Emerging data from European cohorts indicate that the real-world effectiveness of Glucagon-like peptide-1 receptor agonists (GLP1RAs) may fall short of trial-reported outcomes, 9,11,12 potentially due to lower rates of dose escalation and abbreviated treat-ment durations.”
Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.06.017 · Cited by 28
Rubio, M. Á., Carreiro, S. M., Sánchez-Pernaute, A., & Ramos-Levi, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102785 · Cited by 28
Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27
“These contradictory findings suggest that GLP-1 RAs’ effects on DBP may vary across studies [90, 91].”
Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023) · Obesity · doi:10.1002/oby.23752 · Cited by 27
“Recent real-world data studies have replicated the findings of the SCALE and STEP 1 trials, with significant weight loss achieved, and the weight loss was similar across different doses [17, 18].”
BackgroundPharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Horváth, L., Mráz, M., Jude, E. B., & Haluzík, M. (2024) · Drugs · doi:10.1007/s40265-024-02029-0 · Cited by 22
“Other trials have confirmed the weight reduction effect [108–113], including one retrospective trial in a South Korean population ( n = 169, BMI > 27 kg/m 2 ) reporting a weight loss of 7.8 ± 3.5 kg after 180 days (other timepoints: 30 days, 3.2 ± 1.8 kg; 60 days, 4.5 ± 2.3 kg; and 90 days, 6.3 ±…”
BackgroundInfluentialValladales‐Restrepo, L. F., Sánchez-Ramírez, N., Usma-Valencia, A. F., Gaviria‐Mendoza, A., Machado‐Duque, M. E., & Machado‐Alba, J. E. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2178900 · Cited by 21
Valenta, S. T., Stecchi, M., Perazza, F., Nuccitelli, C., Villanova, N., Pironi, L., Atti, A. R., & Petroni, M. L. (2023) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-023-01625-5 · Cited by 14
“…the 28.1% reported in the SCALE Obesity and Prediabetes clinical trial [18], was also higher than that reported in another other real-world study in Switzerland where psychiatric symptoms were not assessed [16], but comparable to that found in patients with established psychiatric diagnosis [30].”
BackgroundResultInfluentialJia, I.-I.-T. T., Bloomfield, G. C., Chen, M. Y., Cunningham, M. H., Azagury, D. E., Alimi, Y., & Prindeze, N. J. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-12086-5 · Cited by 13
Guy, A., Azab, A. N., Liberty, I. F., Afawi, Z., Alhoashla, A., & Abu Tailakh, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15436 · Cited by 12
“14,15,19,20,25 In a study conducted in Canada, it was found that the maintenance dose of liraglutide — 3.0 mg — was typically administered for an average of only 2 – 2.5 months, regardless of the amount of weight loss achieved.”
BackgroundInfluentialXie, J., & Wang, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001320 · Cited by 12
Grosicki, G. J., Thomas, J. G., Dhurandhar, N. V., Lofton, H. F., Heymsfield, S., & Jonnalagadda, S. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16151 · Cited by 12
“9,12,16”
Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting
Ko, H., Kim, J., & Lim, S. K. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22029 · Cited by 12
Alshehri, A., AlFaris, N., Al Qahtani, A. M., Shams, M., & Yahia, M. (2023) · Clinical Obesity · doi:10.1111/cob.12594 · Cited by 11
“The evidence provided by the data from the RWE study can inform the payers, clinicians, and patients about the performance of the intervention outside the narrow research setting boundaries, long-term safety and effectiveness of a drug in a large population, its economic performance and comparative effectiveness with…”
MethodInfluentialLeventhal-Perek, S., Shani, M., & Schonmann, Y. (2023) · Family Practice · doi:10.1093/fampra/cmac141 · Cited by 11
Welling, M. S., de Groot, C. J., Mohseni, M., Meeusen, R. E. H., Boon, M. R., van Haelst, M. M., van den Akker, E. L. T., & van Rossum, E. F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102709 · Cited by 11
“33 – 35 Additionally, discontinuation of treatment due to side effects was comparable to or even less frequent in our study than in the literature for liraglutide (9.1% vs. 9.9%, resp.) and naltrexone-bupropion (16.7% vs. 24.3%, resp.).”
ResultInfluentialBasolo, A., Paolucci, G., Piaggi, P., Angeli, V., Genzano, S. B., Fierabracci, P., Vignali, E., Bologna, C., Salvetti, G., Chiovato, L., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02717-y · Cited by 10
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 10
“Real-world clinical studies have also confirmed the effectiveness of these medications in achieving significant weight loss in settings that lack the resources available in large phase III clinical trials [15–17].”
Oral, A., Küçük, C., & Köse, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206121 · Cited by 8
“…months; in the Canadian study, it was 7.1 ± 5.4% at six months; in another Swiss real-life dataset, it was 8.7 ± 3.1% at four months; in the Korean study, it was 9.1 ± 3.6%; and in the previous study conducted in the Turkish population, it was 11.35 ± 5.22% at six months [10,17,19,20,22,24,25].”
MethodInfluentialGolzarand, M., Toolabi, K., & Mirmiran, P. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01807-4 · Cited by 9
Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.10.019 · Cited by 8
dos Reis, J. R. C., Furtado, P. P. O., Resende, L. D. S., & Reis, B. C. C. (2022) · Revista Eletrônica Acervo Médico · doi:10.25248/reamed.e10289.2022 · Cited by 6
Real‐life use of liraglutide 3 mg in obesity management: The SAX‐RL study
Goëau‐Brissonnière, M., Rives‐Lange, C., Phan, A., Kourti, E., Rassy, N., Lu, E., Barsamian, C., Czernichow, S., & Carette, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15845 · Cited by 4
Hepşen, S., Haymana, C., Helvacı, B. C., Durantaş, H., Torus, B., Çakmak, R., Güven, M., Demirci, İ., Keskin, L., Kiyici, S. K., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02836-5 · Cited by 4
“In line with the previous data, patients with a history of bariatric surgery experienced similar weight loss to those without such a history [11, 28, 29].”
InfluentialOuyang, Y., Xiang, X., Hu, X., Chu, X., Tang, W., & Feng, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1580159 · Cited by 3
“In patients exhibiting persistent/recurrent type 2 diabetes mellitus (T2DM) post-MS and a baseline BMI ≥ 37.0 kg/m², liraglutide achieved a mean weight reduction of 5.26 kg over 26 weeks (12).”
InfluentialKassem, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71293 · Cited by 2
Highlights in the clinical nutrition literature: A critical appraisal of current research
Stoppe, C., Elke, G., Silvstre, S. C. D. M., & Kappus, M. (2024) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2599 · Cited by 1
Exploring the off-label use of liraglutide in the treatment of obesity: a review
Braga, C. B. A., Segundo, J. P. V. A., & Filho, C. A. A. D. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05560-8 · Cited by 1
“These findings sug - gest that while weight loss outcomes may vary based on sex, ethnicity, and lifestyle habits, they appear to be independent of age, initial BMI, and previous bariatric surgery [ 15].”
InfluentialJia, I.-I.-T. T., Bloomfield, G. C., Chen, M. Y., Cunningham, M. H., Wang, A., Daly, S. C., Hinojosa, M. W., Smith, B. R., Nguyen, N. T., Azagury, D. E., et al. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-12940-0 · Cited by 1
A eficácia da liraglutida no tratamento da obesidade - uma revisão integrativa
Fonseca, I. F., Borges, G. D., Gonçalves, G. C., Moreira, F. P., & de Siqueira, E. C. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n6-057
Rajar, U. D. M., Ashraf, N., & Fahim, A. (2024) · ATHENS JOURNAL OF HEALTH & MEDICAL SCIENCES · doi:10.30958/ajhms.11-1-4
Frutuoso, J. F. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/apd3-wq34
Poulter, H., Eberhardt, J., Moore, H., & Windgassen, S. (2020) · TeesRep (Teesside University)
Gilardini, L., Vincenti, V., Croci, M., Martinelli, S., Pasqualinotto, L., Toja, P. M., Cavaggioni, L., & Bertoli, S. (2026) · Journal of Obesity · doi:10.1155/jobe/1224246
“In a Swiss cohort, 42% of subjects reduced their weight by ≥ 5% and had a weight loss of � 4.4 kg after 4 months with a median dose of liraglutide of only 1.5 mg/d [30].”
Influential
Metadata
- Authors
- Haase, C. L., Serratore Achenbach, M. G., Lucrezi, G., Jeswani, N., Maurer, S., & Egermann, U.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- IQVIA (United Kingdom) (GB)
- Venue
- Obesity Facts
- Publisher
- S. Karger AG
- Published
- 2021
- Volume
- 14
- Issue
- 5
- Pages
- 568-576
- ISSN
- 1662-4025 (ISSN-L)
- 1662-4033
- PMC
- PMC8546436
- OpenAlex
- W3193387990
- Semantic Scholar
- a7296933f43e31dd92e5963df57d665e4d6ac1f4
- Cited by
- 41
- References
- 21
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 16 · 2023: 8 · 2022: 5
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Obesity Facts (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- liraglutide, obesity, weight loss, treatment persistence, dose escalation, bariatric surgery, blood pressure, health insurance coverage, cost barriers, real-world effectiveness, GLP-1 receptor agonists, Switzerland, diastolic blood pressure reduction
- MeSH terms
- Liraglutide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Retrospective Studies, Switzerland, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.